Sylvia K. Plevritis - Publications

Affiliations: 
Stanford University, Palo Alto, CA 
Area:
Statistics, Public Health, Operations Research, Oncology, Biostatistics Biology

122 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Ten Haaf K, de Nijs K, Simoni G, Alban A, Cao P, Sun Z, Yong J, Jeon J, Toumazis I, Han SS, Gazelle GS, Kong CY, Plevritis SK, Meza R, de Koning HJ. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X241249182. PMID 38738534 DOI: 10.1177/0272989X241249182  0.738
2023 Karacosta LG, Pancirer D, Preiss JS, Benson JA, Trope W, Shrager JB, Sung AW, Neal JW, Bendall SC, Wakelee H, Plevritis SK. Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports. 13: 21781. PMID 38065965 DOI: 10.1038/s41598-023-46458-5  0.755
2023 Bouchard G, Zhang W, Li I, Ilerten I, Bhattacharya A, Li Y, Trope W, Shrager JB, Kuo C, Tian L, Giaccia AJ, Plevritis SK. The colocatome as a spatial -omic reveals shared microenvironment features between tumour-stroma assembloids and human lung cancer. Biorxiv : the Preprint Server For Biology. PMID 37745466 DOI: 10.1101/2023.09.11.557278  0.782
2023 Kaiser AM, Gatto A, Hanson KJ, Zhao RL, Raj N, Ozawa MG, Seoane JA, Bieging-Rolett KT, Wang M, Li I, Trope WL, Liou DZ, Shrager JB, Plevritis SK, Newman AM, et al. p53 governs an AT1 differentiation programme in lung cancer suppression. Nature. PMID 37468633 DOI: 10.1038/s41586-023-06253-8  0.642
2023 Toumazis I, Cao P, de Nijs K, Bastani M, Munshi V, Hemmati M, Ten Haaf K, Jeon J, Tammemägi M, Gazelle GS, Feuer EJ, Kong CY, Meza R, de Koning HJ, Plevritis SK, et al. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Annals of Internal Medicine. PMID 36745885 DOI: 10.7326/M22-2216  0.744
2022 Zhang W, Li I, Reticker-Flynn NE, Good Z, Chang S, Samusik N, Saumyaa S, Li Y, Zhou X, Liang R, Kong CS, Le QT, Gentles AJ, Sunwoo JB, Nolan GP, ... ... Plevritis SK, et al. Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. Nature Methods. 19: 759-769. PMID 35654951 DOI: 10.1038/s41592-022-01498-z  0.626
2022 Yu A, Li Y, Li I, Ozawa MG, Yeh C, Chiou AE, Trope WL, Taylor J, Shrager J, Plevritis SK. Reconstructing codependent cellular cross-talk in lung adenocarcinoma using REMI. Science Advances. 8: eabi4757. PMID 35302849 DOI: 10.1126/sciadv.abi4757  0.779
2021 Bouchard G, Garcia-Marques FJ, Karacosta LG, Zhang W, Bermudez A, Riley NM, Varma S, Mehl LC, Benson JA, Shrager JB, Bertozzi CR, Pitteri SJ, Giaccia AJ, Plevritis SK. Multi-omics analysis of spatially distinct stromal cells reveals tumor-induced O-glycosylation of the CDK4-pRB axis in fibroblasts at the invasive tumor edge. Cancer Research. PMID 34853070 DOI: 10.1158/0008-5472.CAN-21-1705  0.772
2021 Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SK. A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. Jnci Cancer Spectrum. 5: pkab081. PMID 34738073 DOI: 10.1093/jncics/pkab081  0.742
2021 Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. Jama Oncology. PMID 34673885 DOI: 10.1001/jamaoncol.2021.4942  0.735
2021 Bastani M, Toumazis I, Hedou' J, Leung A, Plevritis SK. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. Journal of the American College of Radiology : Jacr. PMID 34419477 DOI: 10.1016/j.jacr.2021.08.001  0.742
2021 Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer. PMID 34383299 DOI: 10.1002/cncr.33835  0.743
2021 Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. Jama. 325: 988-997. PMID 33687469 DOI: 10.1001/jama.2021.1077  0.724
2020 Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. Lung Cancer (Amsterdam, Netherlands). 147: 154-186. PMID 32721652 DOI: 10.1016/J.Lungcan.2020.07.007  0.767
2020 Criss SD, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine. 172: 706-707. PMID 32422089 DOI: 10.7326/L20-0072  0.435
2020 Su Y, Ko ME, Cheng H, Zhu R, Xue M, Wang J, Lee JW, Frankiw L, Xu A, Wong S, Robert L, Takata K, Yuan D, Lu Y, Huang S, ... ... Plevritis SK, et al. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nature Communications. 11: 2345. PMID 32393797 DOI: 10.1038/S41467-020-15956-9  0.687
2020 Gentles AJ, Hui AB, Feng W, Azizi A, Nair RV, Bouchard G, Knowles DA, Yu A, Jeong Y, Bejnood A, Forgó E, Varma S, Xu Y, Kuong A, Nair VS, ... ... Plevritis SK, et al. A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biology. 21: 107. PMID 32381040 DOI: 10.1186/S13059-020-02019-X  0.78
2020 Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer E, Meza R, Plevritis S. Disparities of national lung cancer screening guidelines in the U.S. population. Journal of the National Cancer Institute. PMID 32040195 DOI: 10.1093/Jnci/Djaa013  0.739
2020 Reticker-Flynn NE, Basto PA, Zhang W, Bejnood A, Kenkel JA, Martins MM, Chang S, Gentles AJ, Sunwoo JB, Plevritis SK, Engleman EG. Abstract PR04: Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immunosuppression Cancer Research. 80: 3419-3419. DOI: 10.1158/1538-7445.Camodels2020-Pr04  0.343
2020 Su Y, Li G, Ko M, Cheng H, Zhu R, Xue M, Robert L, Levine R, Ribas A, Nolan G, Wei W, Plevritis S, Baltimore D, Heath JR. Abstract 6585: Systems biology for investigating drug resistance mechanism of melanoma Cancer Research. 80: 6585-6585. DOI: 10.1158/1538-7445.Am2020-6585  0.699
2019 Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. Jnci Cancer Spectrum. 3: pkz035. PMID 31942534 DOI: 10.1093/Jncics/Pkz035  0.757
2019 Karacosta LG, Anchang B, Ignatiadis N, Kimmey SC, Benson JA, Shrager JB, Tibshirani R, Bendall SC, Plevritis SK. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nature Communications. 10: 5587. PMID 31811131 DOI: 10.1038/S41467-019-13441-6  0.771
2019 Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Annals of Internal Medicine. PMID 31683314 DOI: 10.7326/M19-0322  0.754
2019 Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A comparative modeling analysis of risk-based lung cancer screening strategies. Journal of the National Cancer Institute. PMID 31566216 DOI: 10.1093/Jnci/Djz164  0.751
2019 Knowles DA, Bouchard G, Plevritis S. Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features. Plos Computational Biology. 15: e1006743. PMID 31136571 DOI: 10.1371/Journal.Pcbi.1006743  0.787
2019 Reticker-Flynn NE, Martins MM, Basto PA, Zhang W, Bejnood A, Gentles AJ, Sunwoo JB, Plevritis SK, Engleman EG. Abstract 2703: Lymph node colonization promotes distant tumor metastasis through the induction of systemic immune tolerance Cancer Research. 79: 2703-2703. DOI: 10.1158/1538-7445.Am2019-2703  0.329
2019 Karacosta L, Anchang B, Ignatiadis N, Kimmey S, Benson J, Shrager J, Sung A, Neal J, Wakelee H, Tibshirani R, Bendall S, Plevritis S. OA08.03 A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens Journal of Thoracic Oncology. 14: S226-S227. DOI: 10.1016/J.Jtho.2019.08.449  0.729
2019 Toumazis I, Alagoz O, Leung A, Plevritis S. P2.11-02 Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors Journal of Thoracic Oncology. 14: S792. DOI: 10.1016/J.Jtho.2019.08.1702  0.745
2019 Han S, Chow E, Haaf KT, Toumazis I, Bastani M, Tammemägi M, Jeon J, Feuer E, Meza R, Plevritis S. P1.11-03 Disparities and National Lung Cancer Screening Guidelines in the U.S. Population Journal of Thoracic Oncology. 14: S515-S516. DOI: 10.1016/J.Jtho.2019.08.1076  0.747
2018 Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. Jnci Cancer Spectrum. 2: pky062. PMID 30627694 DOI: 10.1093/Jncics/Pky062  0.322
2018 Bakr S, Gevaert O, Echegaray S, Ayers K, Zhou M, Shafiq M, Zheng H, Benson JA, Zhang W, Leung ANC, Kadoch M, D Hoang C, Shrager J, Quon A, Rubin DL, ... Plevritis SK, et al. A radiogenomic dataset of non-small cell lung cancer. Scientific Data. 5: 180202. PMID 30325352 DOI: 10.1038/Sdata.2018.202  0.383
2018 Han SS, Plevritis SK, Wakelee HA. Caution Needed for Analyzing the Risks of Second Cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 13: e172-e173. PMID 30166015 DOI: 10.1016/J.Jtho.2018.04.018  0.337
2018 Plevritis SK, Berry DA, Mandelblatt JS. Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply. Jama. 319: 2336. PMID 29896623 DOI: 10.1001/Jama.2018.4261  0.343
2018 Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, Ayers K, Bakr S, Gentles AJ, Diehn M, Quon A, West RB, Nair V, van de Rijn M, Napel S, ... Plevritis SK, et al. GFPT2-expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma. Cancer Research. PMID 29760045 DOI: 10.1158/0008-5472.Can-17-2928  0.788
2018 Anchang B, Davis KL, Fienberg HG, Williamson BD, Bendall SC, Karacosta LG, Tibshirani R, Nolan GP, Plevritis SK. DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29654148 DOI: 10.1073/Pnas.1711365115  0.745
2018 Munoz DF, Xu C, Plevritis SK. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 89S-98S. PMID 29554473 DOI: 10.1177/0272989X17737508  0.368
2018 Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 3S-8S. PMID 29554472 DOI: 10.1177/0272989X17737507  0.358
2018 van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M. Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 112S-125S. PMID 29554471 DOI: 10.1177/0272989X17743244  0.4
2018 van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, et al. Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 140S-150S. PMID 29554468 DOI: 10.1177/0272989X17718168  0.358
2018 Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 9S-23S. PMID 29554466 DOI: 10.1177/0272989X17700624  0.383
2018 Munoz DF, Plevritis SK. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 38: 32S-43S. PMID 29554464 DOI: 10.1177/0272989X17743236  0.343
2018 Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. Jama. 319: 154-164. PMID 29318276 DOI: 10.1001/Jama.2017.19130  0.342
2018 Oxnard GR, Maddala T, Hubbell E, Aravanis A, Zhang N, Venn O, Valouev A, Shen L, Patel S, Jamshidi A, Jagadeesh K, Gross S, Filippova D, Beausang JF, Liu MC, ... ... Plevritis S, et al. Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study. Journal of Clinical Oncology. 36: LBA8501-LBA8501. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba8501  0.41
2018 Aravanis AA, Oxnard GR, Maddala T, Hubbell E, Venn O, Jamshidi A, Shen L, Amini H, Beausang JA, Betts C, Civello D, Davydov K, Fazullina S, Filippova D, Gnerre S, ... ... Plevritis SK, et al. Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-343  0.371
2018 Karacosta LG, Anchang B, Kimmey S, Rijn Mvd, Shrager JB, Bendall SC, Plevritis SK. Abstract 4997: Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single cell multidimensional analysis Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4997  0.777
2018 Anchang B, Davis K, Fienberg H, Bendall S, Karacosta L, Nolan G, Plevritis SK. Abstract 2275: Individualized drug combination based on single-cell drug perturbations Cancer Research. 78: 2275-2275. DOI: 10.1158/1538-7445.Am2018-2275  0.751
2018 Zhang W, Plevritis S. Abstract 1297: Studying tumor metabolic reprogramming through integration of metabolomics and transcriptomics Cancer Research. 78: 1297-1297. DOI: 10.1158/1538-7445.Am2018-1297  0.319
2017 Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Plevritis SK, Rubin DL, Leung AN, Napel S, Quon A. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative (18)F FDG-PET/CT metrics. Oncotarget. 8: 52792-52801. PMID 28881771 DOI: 10.18632/Oncotarget.17782  0.342
2017 Zhou M, Leung A, Echegaray S, Gentles A, Shrager JB, Jensen KC, Berry GJ, Plevritis SK, Rubin DL, Napel S, Gevaert O. Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. Radiology. 161845. PMID 28727543 DOI: 10.1148/Radiol.2017161845  0.39
2017 Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes & Control : Ccc. PMID 28702814 DOI: 10.1007/S10552-017-0907-X  0.753
2017 Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. Plos Medicine. 14: e1002277. PMID 28376113 DOI: 10.1371/Journal.Pmed.1002277  0.378
2017 Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, Berry GJ, Guo HH, Lau C, Plevritis SK, Rubin DL, Napel S, Leung AN. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Scientific Reports. 7: 41674. PMID 28139704 DOI: 10.1038/Srep41674  0.327
2017 Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer. PMID 28073150 DOI: 10.1002/Ijc.30602  0.376
2017 Gentles AJ, Hui A, Feng W, Nair RV, Yu A, Shafiq M, Forgo E, Khuong A, Xu Y, Hoang CD, West RB, Rijn Mvd, Diehn M, Plevritis SK. Abstract LB-219: Higher levels of mast cells associate with favorable outcomes in non-small cell lung cancer and correlate with lower malignant cell proliferation Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-219  0.611
2017 Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager J, Ayers K, Nair VS, Gentles A, Diehn M, Quon A, Napel S, Plevritis S. Abstract 4403: FDG uptake in human lung adenocarcinoma associated with invasion through the hexosamine biosynthesis pathway Cancer Research. 77: 4403-4403. DOI: 10.1158/1538-7445.Am2017-4403  0.771
2016 Han S, Rivera GA, Cheng I, Gomez S, Plevritis SK, Wakelee H. PS01.77: Risk-Stratification for Second Primary Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S319-S320. PMID 27969544 DOI: 10.1016/J.Jtho.2016.09.112  0.371
2016 Anchang B, Hart TD, Bendall SC, Qiu P, Bjornson Z, Linderman M, Nolan GP, Plevritis SK. Visualization and cellular hierarchy inference of single-cell data using SPADE. Nature Protocols. 11: 1264-1279. PMID 27310265 DOI: 10.1038/Nprot.2016.066  0.301
2016 Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, ... ... Plevritis S, et al. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine. PMID 26756606 DOI: 10.7326/M15-1536  0.364
2015 Gentles AJ, Bratman SV, Lee LJ, Harris JP, Feng W, Nair RV, Shultz DB, Nair VS, Hoang CD, West RB, Plevritis SK, Alizadeh AA, Diehn M. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute. 107. PMID 26286589 DOI: 10.1093/Jnci/Djv211  0.428
2015 Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine. 21: 938-45. PMID 26193342 DOI: 10.1038/Nm.3909  0.414
2015 Zhao X, Rødland EA, Tibshirani R, Plevritis S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Research : Bcr. 17: 29. PMID 25849221 DOI: 10.1186/S13058-015-0520-4  0.319
2015 Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget. 6: 3563-77. PMID 25784651 DOI: 10.18632/Oncotarget.2969  0.3
2015 Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America. 112: E1116-25. PMID 25713363 DOI: 10.1073/Pnas.1501199112  0.309
2015 Gevaert O, Tibshirani R, Plevritis SK. Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biology. 16: 17. PMID 25631659 DOI: 10.1186/S13059-014-0579-8  0.331
2015 Koch D, Adams S, Gentles A, Anchang B, Sullivan D, Plevritis S, Felsher D. Abstract A48: Gene expression signatures associated with MYC oncogene addiction in lymphoma Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A48  0.319
2015 Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Yue X, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr09  0.438
2015 Anchang B, Fienberg H, Bendall S, Tibshirani R, Plevritis SK. Abstract B1-39: Multi-target drug combinations from single drug responses measured at the level of single cells using Mixture Nested Effects Models (MNEMs) applied to cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-B1-39  0.342
2014 Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, ... ... Plevritis SK, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. Journal of the National Cancer Institute. 106. PMID 25255803 DOI: 10.1093/Jnci/Dju289  0.317
2014 Anchang B, Do MT, Zhao X, Plevritis SK. CCAST: a model-based gating strategy to isolate homogeneous subpopulations in a heterogeneous population of single cells. Plos Computational Biology. 10: e1003664. PMID 25078380 DOI: 10.1371/Journal.Pcbi.1003664  0.344
2014 McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. Plos One. 9: e99978. PMID 24979231 DOI: 10.1371/Journal.Pone.0099978  0.412
2014 Li X, Nadauld L, Ootani A, Corney DC, Pai RK, Gevaert O, Cantrell MA, Rack PG, Neal JT, Chan CWM, Yeung T, Gong X, Yuan J, Wilhelmy J, Robine S, ... ... Plevritis SK, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture Nature Medicine. 20: 769-777. PMID 24859528 DOI: 10.1038/Nm.3585  0.317
2014 Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, ... ... Plevritis SK, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 120: 1713-24. PMID 24577803 DOI: 10.1002/Cncr.28623  0.412
2014 Gallaher J, Babu A, Plevritis S, Anderson AR. Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease. Cancer Research. 74: 426-35. PMID 24408919 DOI: 10.1158/0008-5472.Can-13-0759  0.388
2014 de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 160: 311-20. PMID 24379002 DOI: 10.7326/M13-2316  0.448
2014 Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer (Amsterdam, Netherlands). 83: 189-96. PMID 24355259 DOI: 10.1016/J.Lungcan.2013.11.001  0.378
2013 Gevaert O, Villalobos V, Sikic BI, Plevritis SK. Identification of ovarian cancer driver genes by using module network integration of multi-omics data. Interface Focus. 3: 20130013. PMID 24511378 DOI: 10.1098/Rsfs.2013.0013  0.384
2012 Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, Shrager J, Hoang CD, Plevritis S, Butte AJ, Sweet-Cordero EA. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Research. 72: 5744-56. PMID 22962265 DOI: 10.1158/0008-5472.CAN-12-1097  0.342
2012 Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, Rubin DL, Napel S, Plevritis SK. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. Radiology. 264: 387-96. PMID 22723499 DOI: 10.1148/Radiol.12111607  0.4
2012 Nair VS, Gevaert O, Davidzon G, Napel S, Graves EE, Hoang CD, Shrager JB, Quon A, Rubin DL, Plevritis SK. Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Research. 72: 3725-34. PMID 22710433 DOI: 10.1158/0008-5472.Can-11-3943  0.335
2012 Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1066-77. PMID 22556274 DOI: 10.1158/1055-9965.Epi-12-0149  0.319
2012 Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 497-506. PMID 22231042 DOI: 10.1200/Jco.2011.38.6060  0.348
2012 Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. Cancer Causes & Control : Ccc. 23: 175-85. PMID 22116537 DOI: 10.1007/S10552-011-9866-9  0.464
2012 Newman AM, Gentles AJ, Plevritis SK, Alizadeh AA. Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival. Blood. 120: 2390-2390. DOI: 10.1182/Blood.V120.21.2390.2390  0.413
2012 Plevritis SK. Abstract SY22-01: Multiscale perspective of combination therapy for human cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy22-01  0.395
2012 Vicent S, Gillespie AK, Vakaa D, Khatri P, Chen R, Gevaert O, Clarke N, Plevritis S, Butte A, Sweet-Cordero A. Abstract A41: SOX11 transcriptionally regulates a cytokine-based gene signature in lung cancer-associated fibroblasts (LCAF) to promote tumor growth Clinical Cancer Research. 18: A41-A41. DOI: 10.1158/1078-0432.12Aacriaslc-A41  0.453
2011 Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ. Modeling the impact of population screening on breast cancer mortality in the United States. Breast (Edinburgh, Scotland). 20: S75-81. PMID 22015298 DOI: 10.1016/S0960-9776(11)70299-5  0.355
2011 Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America. 108: 17432-7. PMID 21969595 DOI: 10.1073/Pnas.1107303108  0.312
2011 Shahbaba B, Tibshirani R, Shachaf CM, Plevritis SK. Bayesian gene set analysis for identifying significant biological pathways. Journal of the Royal Statistical Society. Series C, Applied Statistics. 60: 541-557. PMID 21857748 DOI: 10.1111/J.1467-9876.2011.00765.X  0.367
2011 Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 118: 1350-8. PMID 21670469 DOI: 10.1182/Blood-2011-03-345272  0.333
2011 Bendall SC, Simonds EF, Qiu P, Amir el-AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe'er D, Tanner SD, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (New York, N.Y.). 332: 687-96. PMID 21551058 DOI: 10.1126/Science.1198704  0.323
2011 Qiu P, Gentles AJ, Plevritis SK. Discovering biological progression underlying microarray samples. Plos Computational Biology. 7: e1001123. PMID 21533210 DOI: 10.1371/Journal.Pcbi.1001123  0.334
2011 Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Jiang X, Lu X, Romero-Camarero I, Plevritis SK, Martinez-Climent JA, Sanchez-Garcia I, Melnick A, Lossos IS. Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach Blood. 118: 438-438. DOI: 10.1182/Blood.V118.21.438.438  0.31
2011 Gevaert O, Xu J, Hoang C, Leung A, Quon A, Rubin D, Napel S, Plevritis S. Abstract 4148: Integrating medical images and transcriptomic data in non-small cell lung cancer Cancer Research. 71: 4148-4148. DOI: 10.1158/1538-7445.Am2011-4148  0.343
2011 Mandelblatt J, Cronin K, Berry D, Feuer E, de Koning H, Lee S, Plevritis S, Schechter C, Stout N, van Ravesteyn N, Zelen M. S20 Changing the guidelines for breast cancer screening: modeling mammography benefits and harms The Breast. 20: S7-S8. DOI: 10.1016/S0960-9776(11)70023-6  0.362
2010 Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Jama. 304: 2706-15. PMID 21177505 DOI: 10.1001/Jama.2010.1862  0.347
2010 Sahoo D, Seita J, Bhattacharya D, Inlay MA, Weissman IL, Plevritis SK, Dill DL. MiDReG: a method of mining developmentally regulated genes using Boolean implications. Proceedings of the National Academy of Sciences of the United States of America. 107: 5732-7. PMID 20231483 DOI: 10.1073/Pnas.0913635107  0.721
2010 Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 222-31. PMID 19996031 DOI: 10.1200/Jco.2009.22.7991  0.331
2010 Gentles AJ, Alizadeh AA, Alencar AJ, Kohrt HE, Houot R, Goldstein MJ, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Plevritis SK, Lossos IS, Levy R. Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr5  0.35
2009 Inlay MA, Bhattacharya D, Sahoo D, Serwold T, Seita J, Karsunky H, Plevritis SK, Dill DL, Weissman IL. Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes & Development. 23: 2376-81. PMID 19833765 DOI: 10.1101/Gad.1836009  0.716
2009 Pashkevich MA, Sigal BM, Plevritis SK. Modeling the transition of lung cancer from early to advanced stage. Cancer Causes & Control : Ccc. 20: 1559-69. PMID 19629730 DOI: 10.1007/S10552-009-9401-4  0.412
2009 Mandelblatt JS, Cronin KA, Bailey S, Berry DA, Koning HJd, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms Annals of Internal Medicine. 151: 738-747. DOI: 10.1059/0003-4819-151-10-200911170-00010  0.37
2008 Sahoo D, Dill DL, Gentles AJ, Tibshirani R, Plevritis SK. Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biology. 9: R157. PMID 18973690 DOI: 10.1186/Gb-2008-9-10-R157  0.678
2008 Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance Cancer Research. 68: 5132-5142. PMID 18593912 DOI: 10.1158/0008-5472.Can-07-6192  0.707
2007 Sahoo D, Dill DL, Tibshirani R, Plevritis SK. Extracting binary signals from microarray time-course data. Nucleic Acids Research. 35: 3705-12. PMID 17517782 DOI: 10.1093/Nar/Gkm284  0.681
2007 Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Statistics in Medicine. 26: 581-95. PMID 16598706 DOI: 10.1002/Sim.2550  0.7
2006 Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. Journal of the National Cancer Institute. Monographs. 112-21. PMID 17032901 DOI: 10.1093/Jncimonographs/Lgj015  0.332
2006 Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. Journal of the National Cancer Institute. Monographs. 96-105. PMID 17032899 DOI: 10.1093/Jncimonographs/Lgj013  0.37
2006 Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. Journal of the National Cancer Institute. Monographs. 86-95. PMID 17032898 DOI: 10.1093/Jncimonographs/Lgj012  0.712
2006 Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Jama. 295: 2374-84. PMID 16720823 DOI: 10.1001/Jama.295.20.2374  0.315
2005 Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. The New England Journal of Medicine. 353: 1784-92. PMID 16251534 DOI: 10.1056/Nejmoa050518  0.351
2005 Kurian AW, Hartman AR, Mills MA, Ford JM, Daniel BL, Plevritis SK. Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations : An International Journal of Public Participation in Health Care and Health Policy. 8: 221-33. PMID 16098152 DOI: 10.1111/J.1369-7625.2005.00333.X  0.325
2005 Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1082-9. PMID 15894656 DOI: 10.1158/1055-9965.Epi-04-0776  0.302
2005 Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database Breast Cancer Research and Treatment. 89: 47-54. PMID 15666196 DOI: 10.1007/S10549-004-1470-1  0.734
2004 Boer R, Plevritis SK, Clarke LD. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Statistical Methods in Medical Research. 13: 525-538. PMID 15587437 DOI: 10.1191/0962280204Sm381Ra  0.368
2004 Chia YL, Salzman P, Plevritis SK, Glynn PW. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Statistical Methods in Medical Research. 13: 507-24. PMID 15587436 DOI: 10.1191/0962280204Sm380Ra  0.758
2004 Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer. 100: 479-89. PMID 14745863 DOI: 10.1002/Cncr.11926  0.306
2004 Kurian AW, Mills MA, Nowels KW, Plevritis SK, Sigal BM, Chun NM, Kingham KE, Ford JM, Hartman AR. Ductal lavage of non-fluid yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high genetic risk for breast cancer Journal of Clinical Oncology. 22: 9535-9535. DOI: 10.1200/Jco.2004.22.90140.9535  0.307
2002 Plevritis SK, Ikeda DM. Ethical issues in contrast-enhanced magnetic resonance imaging screening for breast cancer. Topics in Magnetic Resonance Imaging : Tmri. 13: 79-84. PMID 12055452 DOI: 10.1097/00002142-200204000-00003  0.341
2001 Plevritis SK. A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Bellman Prize in Mathematical Biosciences. 171: 155-178. PMID 11395049 DOI: 10.1016/S0025-5564(01)00054-2  0.356
1995 Plevritis SK, Macovski A. MRS imaging using anatomically based K-space sampling and extrapolation Magnetic Resonance in Medicine. 34: 686-693. PMID 8544688 DOI: 10.1002/Mrm.1910340506  0.506
1995 Plevritis SK, Macovski A. Spectral Extrapolation of Spatially Bounded Images Ieee Transactions On Medical Imaging. 14: 487-497. DOI: 10.1109/42.414614  0.447
1991 Plevritis SK, Macovski A. Resolution improvement for in-vivo magnetic resonance spectroscopic images Proceedings of Spie - the International Society For Optical Engineering. 1445: 118-127.  0.446
Show low-probability matches.